📰 Access genOway's AACR 2025 posters below

‍

⮞ Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in genO-BRGSF-HIS mice | Download poster here

‍genO-BRGSF-HIS mouse is permissive to cell line xenograft engraftment
TME composition and cell polarization evolve with tumor burden and depend on tumor type in genO-BRGSF-HIS mouse
genO-BRGSF-HIS mouse model is a valuable tool to investigate mechanism of action of immunotherapies

‍
⮞ Preclinical double-humanized genO-hCD47/hSIRPα mouse model and MC38 cell line expressing human CD47 for efficacy and safety assessment of anti-CD47/SIRPα-targeting therapies | Download poster here

Human CD47 and SIRPα expression patterns recapitulate the murine expression of CD47 and SIRPα in genO-hCD47/hSIRPα model
Efficacy and safety of CD47- and/or SIRPα-targeting agents can be assessed in the genO-hCD47/hSIRPα model
genO-hCD47/hSIRPα model is suitable for biodistribution assay for non-invasive in vivo imaging of tumors

‍
⮞ Functional γδ T cells in genO-BRGSF-HIS mice | Download poster here

γδ T cells develop in genO-BRGSF-HIS mice and can be expanded ex vivo and in vivo using Vγ9 expanders
γδ T cells are recruited into the TME of tumor-bearing genO-BRGSF-HIS mice
genO-BRGSF-HIS model brings a new perspective to evaluate therapies designed to expand and activate γδ T cells

‍‍
⮞ genO-hCCR8/hCCL1 humanized model for efficacy assessment of CCR8/CCL1-targeting therapies | Download poster here

Humanization of both CCR8 and CCL1 is required for a functional axis and does not alter immune cell distribution in genO-hCCR8/hCCL1 compared to WT mice
CCR8-targeting therapies can be assessed in genO-hCCR8/hCCL1 model
Human-like expression pattern of CCR8 in genO-BRGSF-HIS naïve Tregs makes it a more suitable model for safety and PD assessment

‍